

**Technical Brief**

**February 2, 2021**

**Emerging SARS-CoV-2 United Kingdom, South Africa, and Brazil Variants  
and Detection by the Lucira COVID-19 All-In-One Test Kit**

The Centers for Disease Control and Prevention (CDC) have highlighted the emergence of three notable SARS-CoV-2 variants<sup>1</sup>:

- (1) B.1.1.7 (also known as 20B/501Y.V1 or Variant of Concern (VOC) 202012/01) first detected in UK,
- (2) B.1.351 (also known as 20C/501Y.V2) first detected in South Africa, and
- (3) P.1 first detected in Brazil.

Lucira Health performs routine surveillance of emerging SARS-CoV-2 strains by periodically evaluating *in silico* reactivity against sequence databases. These evaluations have shown that these three emerging variants are reactive to the Lucira COVID-19 All-In-One Test Kit. The Lucira Health assay targets two non-overlapping regions of the N gene. Hence the detection region is unaffected by the mutations in the spike protein of SARS-CoV-2 in the emerging variant strains. As these particular viral strains become commercially available, Lucira Health intends to perform testing to confirm detection of these strains.

Lucira Health will continue to monitor the situation with emerging variants of SARS-CoV-2.

If you have any questions on the above, please reach out to Technical Support at [techsupport@lucirahealth.com](mailto:techsupport@lucirahealth.com).

<sup>1</sup><https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scientific-brief-emerging-variants.html>